Adaptive BiotechnologiesvsAmgen

ADPT and AMGN stock compared: price, dividend, valuation and results, from SEC filings.

ADPT

Adaptive Biotechnologies Corporation

$28.49

Value $4.6B

+2.22%
ADPT's page

AMGN

Amgen Inc.

$457.93

Value $247B

-0.95%
AMGN's page

Adaptive Biotechnologies (ADPT) has a market value of $4.6B and Amgen (AMGN) $247B. Over the last year, with dividends, ADPT moved +102.1% and AMGN +39.7%. Dividend yield: ADPT none, AMGN 2.17%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ADPT$4.6B

    AMGN$247B

    AMGN is 54 times ADPT

  • Revenue, 12 months

    ADPT$298M

    AMGN$38.9B

    AMGN is 131 times ADPT

  • Net income, 12 months

    ADPT-$71M

    AMGN$9.4B

  • Operating margin

    ADPT-16.2%

    AMGN32.4%

    48.6 points apart

  • ROIC

    ADPT-14.1%

    AMGN16.2%

    30.3 points apart

  • P/E

    ADPT–

    AMGN26.3

  • Dividend yield

    ADPT0.0%

    AMGN2.2%

    2.2 points apart

  • 5-year return

    ADPT-12.6%

    AMGN+158.3%

    170.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ADPT-12.6%

AMGN+158.3%

010020020222023202420252026
Returns by period
PeriodADPTWith dividendsAMGNWith dividends
1 year since November 14, 2025+102.1%Price +102.1%+39.7%Price +36.0%
3 years since November 17, 2023+561.0%+87.7% a yearPrice +561.0%+87.3%+23.3% a yearPrice +72.5%
5 years since November 16, 2021-12.6%-2.7% a yearPrice -12.6%+158.3%+20.9% a yearPrice +123.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ADPTAdaptive BiotechnologiesAMGNAmgen

Valuation

ADPTAMGN
Valuation
Price$28.49$457.93
Market value$4.6B$247B
Enterprise value (EV)$4.3B$288B
P/E–26.3
P/E, 5-year median–23.0
P/B26.217.2
EV/EBIT–22.8
Free cash flow yield–3.9%

Results and growth

ADPTAMGN
Results and growth
Revenue, 12 months$298M$38.9B
Net income, 12 months-$71M$9.4B
Free cash flow, 12 months-$8.8M$9.6B
Earnings per share, 12 months-$0.45$17.25
Revenue growth, year on year54.8%10.0%
Revenue growth a year, past+23.0%over 5 years+7.6%over 5 years
EPS growth a year, past–+2.9%over 5 years

Margins and returns on capital

ADPTAMGN
Margins and returns on capital
Gross margin74.2%70.9%
Operating margin-16.2%32.4%
Net margin-23.7%24.1%
ROIC-14.1%16.2%
ROE-36.8%87.8%

Balance sheet

ADPTAMGN
Balance sheet
Cash$299M$13.2B
Total debt$74M$54.0B
Net debt / EBITDA–2.3
Interest cover-5.3×4.8×

Dividends and buybacks

ADPTAMGN
Dividends and buybacks
Dividend yield–2.2%
Dividend per share, 12 months–$9.94
Dividend growth a year, past–+8.1%over 5 years
Buyback yield––
Shareholder yield–2.2%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ADPT or AMGN

Didn't find what you were looking for?

Ask us
Which is bigger, Adaptive Biotechnologies or Amgen?

By market value, Amgen ($247B) is about 53.5 times Adaptive Biotechnologies ($4.6B), at today's prices.

How did ADPT and AMGN stock do over the last 5 years?

Since November 16, 2021, ADPT's price moved -12.6% and AMGN's +123.0%. With dividends: ADPT -12.6% (-2.7% a year), AMGN +158.3% (+20.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, ADPT or AMGN?

The dividend yield at today's price is none for Adaptive Biotechnologies and 2.17% for Amgen. Over the last twelve months they paid – and $9.94 per share.

Which has the higher profit margins, Adaptive Biotechnologies or Amgen?

Over the last twelve months, the net margin was -23.7% for Adaptive Biotechnologies and 24.1% for Amgen, and the operating margin -16.2% and 32.4%. Revenue was $298M and $38.9B.

Which is the better investment, Adaptive Biotechnologies or Amgen?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.